Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 24, 2016, Pages E3413-E3422

  Li, Hui ^a   Wang, Shuyi ^a   Kong, Rui ^a   Ding, Wenge ^a   Lee, Fang Hua ^a   Parker, Zahra ^a   Kim, Eunlim ^a   Learn, Gerald H ^a   Hahn, Paul ^a   Policicchio, Ben ^b   Brocca Cofano, Egidio ^b   Deleage, Claire ^c   Hao, Xingpei ^c   Chuang, Gwo Yu ^d   Gorman, Jason ^d   Gardner, Matthew ^e   Lewis, Mark G ^f   Hatziioannou, Theodora ^g   Santra, Sampa ^h   Apetrei, Cristian ^b   Pandrea, Ivona ^b   Alam, S Munir ⁱ   Liao, Hua Xin ⁱ   Shen, Xiaoying ⁱ   Tomaras, Georgia D ⁱ   Farzan, Michael ^e   Chertova, Elena ^c   Keele, Brandon F ^c   Estes, Jacob D ^c   Lifson, Jeffrey D ^c   Doms, Robert W ^j   Montefiori, David C ⁱ   Haynes, Barton F ⁱ   Sodroski, Joseph G ^k   Kwong, Peter D ^c   Hahn, Beatrice H ^a   Shaw, George M ^a   more..

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e SCRIPPS RESEARCH INSTITUTE   (United States)

^f BIOQUAL INC   (United States)

^g ROCKEFELLER UNIVERSITY   (United States)

^h BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

ⁱ DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^k HARVARD MEDICAL SCHOOL   (United States)

more..

Author keywords

CD4; HIV 1 envelope; HIV AIDS; SHIV

Indexed keywords

B LYMPHOCYTE RECEPTOR; GAG PROTEIN; NEUTRALIZING ANTIBODY; VIRUS DNA; VIRUS ENVELOPE PROTEIN; CD4 ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE A; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE B; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE C; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE D; IMMUNOPATHOGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; RHESUS MONKEY; SEROCONVERSION; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS ENTRY; VIRUS REPLICATION; VIRUS TRANSMISSION; WESTERN BLOTTING; AMINO ACID SUBSTITUTION; ANIMAL; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; MISSENSE MUTATION; PHYSIOLOGY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME;

AMINO ACID SUBSTITUTION; ANIMALS; ANTIGENS, CD4; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV INFECTIONS; HIV-1; HUMANS; MACACA MULATTA; MUTATION, MISSENSE; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS REPLICATION;

EID: 84974718820     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1606636113     Document Type: Article

References (117)

1. Sharma A, Boyd DF, Overbaugh J (2015) Development of SHIVs with circulating, transmitted HIV-1 variants. J Med Primatol 44(5):296-300.
2. Hatziioannou T, Evans DT (2012) Animal models for HIV/AIDS research. Nat Rev Microbiol 10(12):852-867.
3. Santra S, et al. (2015) Human on-neutralizing HIV-1 envelope monoclonal antibodies limit the number of founder viruses during SHIV mucosal infection in rhesus macaques. PLoS Pathog 11(8):e1005042.
4. Hessell AJ, et al. (2007) Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449(7158):101-104.
5. Hessell AJ, et al. (2009) Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med 15(8):951-954.
6. Mascola JR (2002) Passive transfer studies to elucidate the role of antibody-mediated protection against HIV-1. Vaccine 20(15):1922-1925.
7. Veazey RS, et al. (2003) Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med 9(3):343-346.
8. Walker LM, et al. (2011) Rapid development of glycan-specific, broad, and potent anti-HIV-1 gp120 neutralizing antibodies in an R5 SIV/HIV chimeric virus infected macaque. Proc Natl Acad Sci USA 108(50):20125-20129.
9. Shingai M, et al. (2012) Most rhesus macaques infected with the CCR5-tropic SHIV(AD8) generate cross-reactive antibodies that neutralize multiple HIV-1 strains. Proc Natl Acad Sci USA 109(48):19769-19774.
10. Yamamoto T, et al. (2015) Quality and quantity of TFH cells are critical for broad antibody development in SHIVAD8 infection. Sci Transl Med 7(298):298ra120.
11. Francica JR, et al.; NISC Comparative Sequencing Program (2015) Analysis of immunoglobulin transcripts and hypermutation following SHIV(AD8) infection and protein-plus-adjuvant immunization. Nat Commun 6:6565.
12. Barouch DH, et al. (2013) Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 503(7475):224-228.
13. Shingai M, et al. (2013) Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 503(7475):277-280.
14. Reimann KA, et al. (1996) A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. J Virol 70(10):6922-6928.
15. Reimann KA, et al. (1996) An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high in vivo replicative capacity to a chimeric simian/human immunodeficiency virus in rhesus monkeys. J Virol 70(5):3198-3206.
16. Harouse JM, Gettie A, Tan RC, Blanchard J, Cheng-Mayer C (1999) Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs. Science 284(5415):816-819.
17. Harouse JM, et al. (2001) Mucosal transmission and induction of simian AIDS by CCR5- specific simian/human immunodeficiency virus SHIV(SF162P3). J Virol 75(4):1990-1995.
18. Song RJ, et al. (2006) Molecularly cloned SHIV-1157ipd3N4: A highly replicationcompetent, mucosally transmissible R5 simian-human immunodeficiency virus encoding HIV clade C Env. J Virol 80(17):8729-8738.
19. Nishimura Y, et al. (2010) Generation of the pathogenic R5-tropic simian/human immunodeficiency virus SHIVAD8 by serial passaging in rhesus macaques. J Virol 84(9):4769-4781.
20. Karlsson GB, et al. (1997) Characterization of molecularly cloned simian-human immunodeficiency viruses causing rapid CD4+ lymphocyte depletion in rhesus monkeys. J Virol 71(6):4218-4225.
21. Ren W, et al. (2013) Generation of lineage-related, mucosally transmissible subtype C R5 simian-human immunodeficiency viruses capable of AIDS development, induction of neurological disease, and coreceptor switching in rhesus macaques. J Virol 87(11): 6137-6149.
22. Zhuang K, et al. (2014) Emergence of CD4 independence envelopes and astrocyte infection in R5 simian-human immunodeficiency virus model of encephalitis. J Virol 88(15):8407-8420.
23. Keele BF, et al. (2008) Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA 105(21):7552-7557.
24. Parrish NF, et al. (2013) Phenotypic properties of transmitted founder HIV-1. Proc Natl Acad Sci USA 110(17):6626-6633.
25. Finzi A, et al. (2012) Lineage-specific differences between human and simian immunodeficiency virus regulation of gp120 trimer association and CD4 binding. J Virol 86(17):8974-8986.
26. Humes D, Emery S, Laws E, Overbaugh J (2012) A species-specific amino acid difference in the macaque CD4 receptor restricts replication by global circulating HIV-1 variants representing viruses from recent infection. J Virol 86(23):12472-12483.
27. Meyerson NR, Sharma A, Wilkerson GK, Overbaugh J, Sawyer SL (2015) Identification of owl monkey CD4 receptors broadly compatible with early-stage HIV-1 isolates. J Virol 89(16):8611-8622.
28. Li J, Lord CI, Haseltine W, Letvin NL, Sodroski J (1992) Infection of cynomolgus monkeys with a chimeric HIV-1/SIVmac virus that expresses the HIV-1 envelope glycoproteins. J Acquir Immune Defic Syndr 5(7):639-646.
29. Pal R, et al. (2003) Characterization of a simian human immunodeficiency virus encoding the envelope gene from the CCR5-tropic HIV-1 Ba-L. J Acquir Immune Defic Syndr 33(3):300-307.
30. Humes D, Overbaugh J (2011) Adaptation of subtype a human immunodeficiency virus type 1 envelope to pig-tailed macaque cells. J Virol 85(9):4409-4420.
31. Boyd DF, et al. (2015) Mutations in HIV-1 envelope that enhance entry with the macaque CD4 receptor alter antibody recognition by disrupting quaternary interactions within the trimer. J Virol 89(2):894-907.
32. Siddappa NB, et al. (2009) Neutralization-sensitive R5-tropic simian-human immunodeficiency virus SHIV-2873Nip, which carries env isolated from an infant with a recent HIV clade C infection. J Virol 83(3):1422-1432.
33. Siddappa NB, et al. (2010) R5 clade C SHIV strains with tier 1 or 2 neutralization sensitivity: Tools to dissect env evolution and to develop AIDS vaccines in primate models. PLoS One 5(7):e11689.
34. Gautam R, et al. (2012) Pathogenicity and mucosal transmissibility of the R5-tropic simian/human immunodeficiency virus SHIV(AD8) in rhesus macaques: Implications for use in vaccine studies. J Virol 86(16):8516-8526.
35. Chang HW, et al. (2015) Generation and evaluation of clade C simian-human immunodeficiency virus challenge stocks. J Virol 89(4):1965-1974.
36. Asmal M, et al. (2015) Infection of monkeys by simian-human immunodeficiency viruses with transmitted/founder clade C HIV-1 envelopes. Virology 475:37-45.
37. Del Prete GQ, et al. (2014) Selection of unadapted, pathogenic SHIVs encoding newly transmitted HIV-1 envelope proteins. Cell Host Microbe 16(3):412-418.
38. Tartaglia LJ, et al. (2016) Production of mucosally transmissible SHIV challenge stocks from HIV-1 circulating recombinant form 01-AE env sequences. PLoS Pathog 12(2):e1005431.
39. Alexander L, Denekamp L, Czajak S, Desrosiers RC (2001) Suboptimal nucleotides in the infectious, pathogenic simian immunodeficiency virus clone SIVmac239. J Virol 75(8):4019-4022.
40. Li JT, et al. (1995) Persistent infection of macaques with simian-human immunodeficiency viruses. J Virol 69(11):7061-7067.
41. Del Prete GQ, et al. (2013) Comparative characterization of transfection- and infection- derived simian immunodeficiency virus challenge stocks for in vivo nonhuman primate studies. J Virol 87(8):4584-4595.
42. Lopker M, et al. (2016) Derivation and characterization of pathogenic transmitted/founder molecular clones from SIVsmE660 and SIVmac251 following mucosal infection. J Virol, in press.
43. Fennessey CM, et al. (2015) Generation and characterization of a SIVmac239 clone corrected at four suboptimal nucleotides. Retrovirology 12:49.
44. Xiang SH, et al. (2002) Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoprotein. J Virol 76(19):9888-9899.
45. Pancera M, et al. (2014) Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature 514(7523):455-461.
46. Kwon YD, et al. (2015) Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env. Nat Struct Mol Biol 22(7):522-531.
47. Munro JB, et al. (2014) Conformational dynamics of single HIV-1 envelope trimers on the surface of native virions. Science 346(6210):759-763.
48. Kwong PD, et al. (1998) Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393(6686):648-659.
49. Dey B, et al. (2007) Characterization of human immunodeficiency virus type 1 monomeric and trimeric gp120 glycoproteins stabilized in the CD4-bound state: Antigenicity, biophysics, and immunogenicity. J Virol 81(11):5579-5593.
50. Finzi A, et al. (2010) Topological layers in the HIV-1 gp120 inner domain regulate gp41 interaction and CD4-triggered conformational transitions. Mol Cell 37(5):656-667.
51. Li Y, et al. (1991) Molecular characterization of human immunodeficiency virus type 1 cloned directly from uncultured human brain tissue: Identification of replicationcompetent and -defective viral genomes. J Virol 65(8):3973-3985.
52. Baalwa J, et al. (2013) Molecular identification, cloning and characterization of transmitted/founder HIV-1 subtype A, D and A/D infectious molecular clones. Virology 436(1):33-48.
53. Liao HX, et al.; NISC Comparative Sequencing Program (2013) Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 496(7446):469-476.
54. Goo L, Chohan V, Nduati R, Overbaugh J (2014) Early development of broadly neutralizing antibodies in HIV-1-infected infants. Nat Med 20(6):655-658.
55. Gao F, et al. (2014) Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies. Cell 158(3):481-491.
56. Sanders RW, et al. (2015) HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers. Science 349(6244):aac4223.
57. Wu X, et al. (2006) Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant. J Virol 80(2):835-844.
58. Sanders RW, et al. (2013) A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not nonneutralizing antibodies. PLoS Pathog 9(9):e1003618.
59. Julien JP, et al. (2013) Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 342(6165):1477-1483.
60. Lyumkis D, et al. (2013) Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science 342(6165):1484-1490.
61. Wei X, et al. (2002) Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 46(6):1896-1905.
62. Bannert N, Schenten D, Craig S, Sodroski J (2000) The level of CD4 expression limits infection of primary rhesus monkey macrophages by a T-tropic simian immunodeficiency virus and macrophagetropic human immunodeficiency viruses. J Virol 74(23):10984-10993.
63. Wilen CB, et al. (2011) Phenotypic and immunologic comparison of clade B transmitted/founder and chronic HIV-1 envelope glycoproteins. J Virol 85(17):8514-8527.
64. Decker JM, et al. (2005) Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J Exp Med 201(9):1407-1419.
65. Kwong PD, et al. (2002) HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420(6916):678-682.
66. Salazar-Gonzalez JF, et al. (2009) Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med 206(6):1273-1289.
67. Brown CR, et al. (2007) Unique pathology in simian immunodeficiency virus-infected rapid progressor macaques is consistent with a pathogenesis distinct from that of classical AIDS. J Virol 81(11):5594-5606.
68. Fiebig EW, et al. (2003) Dynamics of HIV viremia and antibody seroconversion in plasma donors: Implications for diagnosis and staging of primary HIV infection. AIDS 17(13):1871-1879.
69. Michael NL, et al. (1997) Rapid disease progression without seroconversion following primary human immunodeficiency virus type 1 infection - Evidence for highly susceptible human hosts. J Infect Dis 175(6):1352-1359.
70. Seaman MS, et al. (2010) Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol 84(3):1439-1452.
71. deCamp A, et al. (2014) Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 88(5):2489-2507.
72. Robb ML, et al. (May 18, 2016) Prospective study of acute HIV-1 infection in adults in East Africa and Thailand. N Engl J Med, 10.1056/NEJMoa1508952.
73. Ndhlovu ZM, et al. (2015) Magnitude and kinetics of CD8+ T cell activation during hyperacute HIV infection impact viral set point. Immunity 43(3):591-604.
74. Abrahams MR, et al. (2009) Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants. J Virol 83(8):3556-3567.
75. Bonsignori M, et al. (2016) Maturation pathway from germline to broad HIV-1 neutralizer of a CD4-mimic antibody. Cell 165(2):449-463.
76. Barouch DH, et al. (2013) Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell 155(3):531-539.
77. Burton DR, Mascola JR (2015) Antibody responses to envelope glycoproteins in HIV-1 infection. Nat Immunol 16(6):571-576.
78. West AP, Jr, et al. (2014) Structural insights on the role of antibodies in HIV-1 vaccine and therapy. Cell 156(4):633-648.
79. Myszka DG, et al. (2000) Energetics of the HIV gp120-CD4 binding reaction. Proc Natl Acad Sci USA 97(16):9026-9031.
80. Pancera M, et al. (2010) Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility. Proc Natl Acad Sci USA 107(3):1166-1171.
81. Kwon YD, et al. (2012) Unliganded HIV-1 gp120 core structures assume the CD4- bound conformation with regulation by quaternary interactions and variable loops. Proc Natl Acad Sci USA 109(15):5663-5668.
82. Haim H, et al. (2009) Soluble CD4 and CD4-mimetic compounds inhibit HIV-1 infection by induction of a short-lived activated state. PLoS Pathog 5(4):e1000360.
83. Kassa A, et al. (2009) Transitions to and from the CD4-bound conformation are modulated by a single-residue change in the human immunodeficiency virus type 1 gp120 inner domain. J Virol 83(17):8364-8378.
84. Désormeaux A, et al. (2013) The highly conserved layer-3 component of the HIV-1 gp120 inner domain is critical for CD4-required conformational transitions. J Virol 87(5):2549-2562.
85. Zhou T, et al. (2007) Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445(7129):732-737.
86. Haim H, et al. (2011) Contribution of intrinsic reactivity of the HIV-1 envelope glycoproteins to CD4-independent infection and global inhibitor sensitivity. PLoS Pathog 7(6):e1002101.
87. Haim H, et al. (2013) Modeling virus- and antibody-specific factors to predict human immunodeficiency virus neutralization efficiency. Cell Host Microbe 14(5):547-558.
88. Andrabi R, et al. (2015) Identification of common features in prototype broadly neutralizing antibodies to HIV envelope V2 apex to facilitate vaccine design. Immunity 43(5):959-973.
89. Gorman J, et al. (2016) Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design. Nat Struct Mol Biol 23(1):81-90.
90. Jardine JG, et al. (2015) HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen. Science 349(6244):156-161.
91. Dosenovic P, et al. (2015) Immunization for HIV-1 broadly neutralizing antibodies in human Ig knockin mice. Cell 161(7):1505-1515.
92. Haynes BF, Kelsoe G, Harrison SC, Kepler TB (2012) B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol 30(5):423-433.
93. Bhiman JN, et al. (2015) Viral variants that initiate and drive maturation of V1V2- directed HIV-1 broadly neutralizing antibodies. Nat Med 21(11):1332-1336.
94. Wei X, et al. (2003) Antibody neutralization and escape by HIV-1. Nature 422(6929):307-312.
95. Louder MK, et al. (2005) HIV-1 envelope pseudotyped viral vectors and infectious molecular clones expressing the same envelope glycoprotein have a similar neutralization phenotype, but culture in peripheral blood mononuclear cells is associated with decreased neutralization sensitivity. Virology 339(2):226-238.
96. Hatziioannou T, et al. (2014) HIV-1-induced AIDS in monkeys. Science 344(6190): 1401-1405.
97. Larkin MA, et al. (2007) Clustal W and Clustal X version 2.0. Bioinformatics 23(21): 2947-2948.
98. Guindon S, et al. (2010) New algorithms and methods to estimate maximum-likelihood phylogenies: Assessing the performance of PhyML 3.0. Syst Biol 59(3):307-321.
99. Delano W (2002) The PyMOL Molecular Graphics System (DeLano Scientific, San Carlos, CA).
100. Davis IW, Murray LW, Richardson JS, Richardson DC (2004) MOLPROBITY: Structure validation and all-atom contact analysis for nucleic acids and their complexes. Nucleic Acids Res 32(Web Server issue):W615-9.
101. Huang CC, et al. (2004) Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120. Proc Natl Acad Sci USA 101(9):2706-2711.
102. Garces F, et al. (2015) Affinity maturation of a potent family of HIV antibodies is primarily focused on accommodating or avoiding glycans. Immunity 43(6):1053-1063.
103. Pandrea I, et al. (2011) Functional cure of SIVagm infection in rhesus macaques results in complete recovery of CD4+ T cells and is reverted by CD8+ cell depletion. PLoS Pathog 7(8):e1002170.
104. Pandrea I, et al. (2008) Simian immunodeficiency virus SIVagm dynamics in African green monkeys. J Virol 82(7):3713-3724.
105. Puffer BA, et al. (2002) CD4 independence of simian immunodeficiency virus Envs is associated with macrophage tropism, neutralization sensitivity, and attenuated pathogenicity. J Virol 76(6):2595-2605.
106. Campeau E, et al. (2009) A versatile viral system for expression and depletion of proteins in mammalian cells. PLoS One 4(8):e6529.
107. Li Y, et al. (1992) Complete nucleotide sequence, genome organization, and biological properties of human immunodeficiency virus type 1 in vivo: Evidence for limited defectiveness and complementation. J Virol 66(11):6587-6600.
108. André S, et al. (1998) Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. J Virol 72(2):1497-1503.
109. AlamSM, et al. (2013) Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion. J Virol 87(3):1554-1568.
110. Gardner MR, et al. (2015) AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. Nature 519(7541):87-91.
111. Bess JW, Jr, Gorelick RJ, Bosche WJ, Henderson LE, Arthur LO (1997) Microvesicles are a source of contaminating cellular proteins found in purified HIV-1 preparations. Virology 230(1):134-144.
112. Gluschankof P, Mondor I, Gelderblom HR, Sattentau QJ (1997) Cell membrane vesicles are a major contaminant of gradient-enriched human immunodeficiency virus type-1 preparations. Virology 230(1):125-133.
113. Dimmic MW, Rest JS, Mindell DP, Goldstein RA (2002) rtREV: An amino acid substitution matrix for inference of retrovirus and reverse transcriptase phylogeny. J Mol Evol 55(1):65-73.
114. Tomaras GD, et al. (2008) Initial B-cell responses to transmitted human immunodeficiency virus type 1: Virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol 82(24):12449-12463.
115. Hansen SG, et al. (2013) Immune clearance of highly pathogenic SIV infection. Nature 502(7469):100-104.
116. Zhou T, et al. (2010) Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329(5993):811-817.
117. Zamyatnin AA (1972) Protein volume in solution. Prog Biophys Mol Biol 24:107-123.